All In Biotech

Drug Trial Radar · NCT05456880

BEACON: A Study Evaluating the Safety and Efficacy of BEAM-101 in Patients With Severe Sickle Cell Disease

A Phase 1/2 Study Evaluating the Safety and Efficacy of a Single Dose of Autologous CD34+ Base Edited Hematopoietic Stem Cells (BEAM-101) in Patients With Sickle Cell Disease and Severe Vaso-Occlusive Crises (Beacon Trial)

Last checked: Nov 19, 2026Latest source record: Dec 16, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

15

Planned (sponsor's estimate)

Start

Aug 30, 2022

Primary completion

Feb 2028

Study completion Feb 2028

Sponsor

Lead sponsor
Beam Therapeutics Inc.Industry
Sponsor type
Industry
First posted
Jul 13, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 12 years, up to 35 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is an open-label, single-arm, multicenter, Phase 1/2 study evaluating the safety and efficacy of the administration of autologous base edited CD34+ HSPCs (BEAM-101) in patients with severe SCD

Conditions

  • Sickle Cell Disease

Interventions

  • BEAM-101Biological

    Single dose of BEAM-101 administered by IV following myeloablative conditioning with busulfan

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change in annualized number of severe VOCs (Vascular-occlusive Crisis) relative to baselineTime frame: 6 months to time of analysis as compared to baseline
  2. Proportion of patients with successful neutrophil engraftmentTime frame: BEAM-101 administration to month 24
  3. Time to neutrophil engraftmentTime frame: BEAM-101 administration to month 24
  4. Time to platelet engraftmentTime frame: BEAM-101 administration to month 24
  5. Transplant-related mortality within 100 days after beam-101 treatmentTime frame: BEAM-101 administration to day 100
  6. Safety and tolerability assessments based on frequency, severity and seriousness of adverse events (AE's)Time frame: BEAM-101 administration through month 24

Locations

19 sites in 1 country. Site status is shown where the registry gives one.

  • University of Alabama at Birmingham

    Birmingham, Alabama

  • Phoenix Children's Hospital

    Phoenix, Arizona

  • Mayo Clinic Florida

    Jacksonville, Florida

  • University of Miami

    Miami, Florida

  • Children's Healthcare of Atlanta - Aflac Cancer and Blood Disorders Center - Egleston Hospital

    Atlanta, Georgia

  • Boston Children's Hospital

    Boston, Massachusetts

  • Henry Ford Cancer Center

    Detroit, Michigan

  • University of Minnesota

    Minneapolis, Minnesota

  • Washington University School of Medicine in St. Louis

    St Louis, Missouri

  • Hackensack University Medical Center

    Hackensack, New Jersey

  • Columbia University Irving Medical Center

    New York, New York

  • Memorial Sloan Kettering Cancer Center

    New York, New York

  • University Hospitals Cleveland Medical Center

    Cleveland, Ohio

  • The Cleveland Clinic Foundation

    Cleveland, Ohio

  • Children's Hospital of Philadelphia

    Philadelphia, Pennsylvania

  • Medical University of South Carolina

    Charleston, South Carolina

  • St Jude Children's Research Hospital

    Memphis, Tennessee

  • The Children's Hospital at TriStar Centennial

    Nashville, Tennessee

  • Medical College of Wisconsin

    Milwaukee, Wisconsin

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.